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Abstract
Background:  Metabolic syndrome increases cardiovascular risk. Limited information on its
prevalence in Latin America is available. The Cardiovascular Risk Factor Multiple Evaluation in Latin
America (CARMELA) study included assessment of metabolic syndrome in 7 urban Latin American
populations.
Methods: CARMELA was a cross-sectional, population-based, observational study conducted in
Barquisimeto, Venezuela; Bogota, Colombia; Buenos Aires, Argentina; Lima, Peru; Mexico City,
Mexico; Quito, Ecuador; and Santiago, Chile. The prevalence of metabolic syndrome, defined
according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP
III), and associated carotid atherosclerosis were investigated in 11,502 participants aged 25 to 64
years.
Results: Across CARMELA cities, metabolic syndrome was most prevalent in Mexico City (27%)
and Barquisimeto (26%), followed by Santiago (21%), Bogota (20%), Lima (18%), Buenos Aires
(17%), and Quito (14%). In nondiabetic participants, prevalence was slightly lower but followed a
comparable ranking. Overall, 59%, 59%, and 73% of women with high triglycerides, hypertension,
or glucose abnormalities, respectively, and 64%, 48% and 71% of men with abdominal obesity,
hypertension, or glucose abnormalities, respectively, had the full metabolic syndrome. Prevalence
of metabolic syndrome increased with age, markedly so in women. Mean common carotid artery
intima-media thickness (CCAIMT) and prevalence of carotid plaque increased steeply with
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increasing numbers of metabolic syndrome components; mean CCAIMT was higher and plaque
more prevalent in participants with metabolic syndrome than without.
Conclusion: The prevalence of metabolic syndrome and its components by NCEP ATP III criteria
was substantial across cities, ranging from 14% to 27%. CARMELA findings, including evidence of
the association of metabolic syndrome and carotid atherosclerosis, should inform appropriate
clinical and public health interventions.
Background
The concept of the metabolic syndrome has developed in
stages over the past 80 years; it is now recognized that the
combination of abdominal obesity, glucose metabolism
abnormalities, hypertension, and dyslipidemia, accompa-
nied by prothrombotic and proinflammatory states, leads
to type 2 diabetes and vascular diseases, including coro-
nary heart disease and stroke [1,2].
Metabolic syndrome predicts total, cardiovascular, and
coronary heart disease mortality; in fact, the presence of
even 1 or 2 components of the metabolic syndrome
increases overall mortality compared with the absence of
any component of the metabolic syndrome [3-6]. A 65%
excess risk has been estimated for cardiovascular disease
in individuals with the metabolic syndrome [7]. Meta-
bolic syndrome even predicts the occurrence of sudden
death, independent of the presence of other cardiovascu-
lar risk factors [8]. Metabolic syndrome also predicts the
incidence and progression of carotid atherosclerosis [9].
As reviewed recently, worldwide prevalence of metabolic
syndrome ranges from <10% to as much as 84%, depend-
ing on age, region, urban or rural environment, ethnicity,
and the definition of metabolic syndrome used [10-12].
In the United States, between 1994 and 2000, prevalence
of metabolic syndrome in adults increased from 23% to
27% along with an increase in obesity and physical inac-
tivity [13]. Developing regions like Latin America, under-
going sea change in the lifestyle factors contributing to the
metabolic syndrome, may see even greater increases in
prevalence over a relatively short span of time. Local pub-
lic health and clinical efforts to stem morbidity and mor-
tality from the metabolic syndrome must be based on the
relevant local prevalence of its components. The Cardio-
vascular Risk Factor Multiple Evaluation in Latin America
(CARMELA) study investigated risk factors for cardiovas-
cular disease in 7 Latin American cities, as reported else-
where [14]. With cardiovascular risk and clinical
interventions in mind, the National Cholesterol Educa-
tion Program Adult Treatment Panel III (NCEP ATP III)
criteria [2] were used to assess metabolic syndrome prev-
alence in CARMELA cities. The association of metabolic
syndrome with mean common carotid artery intima-
media thickness (CCAIMT), as a marker of carotid athero-
sclerosis, was also investigated.
Methods
Study Design
CARMELA was a multistage, cross-sectional epidemio-
logic study conducted between September 2003 and
August 2005, in Barquisimeto, Venezuela; Bogota,
Colombia; Buenos Aires, Argentina; Lima, Peru; Mexico
City, Mexico; Quito, Ecuador; and Santiago, Chile. The
study was conducted according to the Declaration of Hel-
sinki and the Guides for Good Clinical Practice. Approxi-
mately 1,600 participants per city between the ages of 25
and 64 years were included, stratified by sex and age (10-
year groups). The study was approved by an institutional
review committee in all participating cities, and all sub-
jects gave informed consent. Study methods are described
in detail elsewhere [14].
Anthropometry
Waist circumference was measured at the midpoint
between the last rib and the iliac crest with participants
standing and wearing only undergarments.
Blood Glucose and Lipids
Participants were asked to refrain from using laxatives
containing glycerin for 48 hours and from consuming
glycerin-containing products and other sweets for 24
hours prior to blood sampling. Blood was drawn in the
fasting state; only water, black coffee, or unsweetened tea
and medications other than antidiabetic medications
were permitted during the 12 hours prior to sampling.
Following the sampling, participants were allowed to
resume their usual antidiabetic medication. Plasma glu-
cose was assayed within 6 hours. Serum was assayed for
high density lipoprotein cholesterol and triglycerides.
Blood Pressure
Blood pressure (at rest) was measured with the participant
seated. Two readings were taken 5 minutes apart; if differ-
ent by >5 mm Hg, measurements were repeated until 2
concordant readings were obtained.
Measurement of CCAIMT
Far wall CCAIMT was evaluated according to the Man-
nheim intima-media thickness consensus [15]. Both com-
mon carotid arteries were examined by B-mode
ultrasonography with participants in the supine position,
using phased array 7.5 MHz transducers and ultrasoundCardiovascular Diabetology 2009, 8:52 http://www.cardiab.com/content/8/1/52
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apparatus no older than 7 years. M'AthStd®  software
(Intelligence in Medical Technologies, Paris, France) auto-
matically measured the CCAIMT; measurements were
taken over a 10 mm length and averaged, and quality of
acquisition was evaluated. Data were analyzed at a central
laboratory at Intelligence in Medical Technologies, Paris,
France.
Definitions
Diabetes was defined as a fasting plasma glucose level ≥
7.0 mmol/l (126 mg/dL) [16] or self-reported diabetes.
Metabolic syndrome was defined by NCEP ATP III criteria
as the presence of 3 or more of the following: waist >102
cm in men, >88 cm in women; triglycerides ≥ 1.70 mmol/
l (150 mg/dL); high density lipoprotein cholesterol
(HDL-C) <1.03 mmol/l (40 mg/dL) in men, <1.29 mmol/
l (50 mg/dL) in women; blood pressure ≥ 130/85 mm Hg;
and fasting plasma glucose ≥ 6.11 mmol/l (110 mg/dL) or
self-reported diabetes [2].
Statistical Analysis
Statistical processing addressed the nonequal probability
character of the sample and the structure of the design to
generate data adjusted for the age and sex distribution of
the population of each city. Means and prevalence along
with their 95% confidence intervals were estimated by
survey analysis procedures (SAS Software, Release 9.1,
Cary, North Carolina, USA), taking into account the
multistage stratified sampling design via CLUSTER and
STRATA statements.
Results
A total of 11,550 participants between the ages of 25 and
64 years were enrolled in CARMELA between September
2003 and August 2005. Data for 11,502 participants were
evaluable for metabolic syndrome: Barquisimeto, n =
1,836; Bogotá, n = 1,550; Buenos Aires, n = 1,476; Lima,
n = 1,645; Mexico City, n = 1,720; Quito, n = 1,627; and
Santiago, n = 1,648. Per the study design, age and sex dis-
tribution was relatively even for each city.
Prevalence of the Metabolic Syndrome in the Overall 
CARMELA Population
Metabolic syndrome was most prevalent in Mexico City
(27%) and Barquisimeto (26%), followed by Santiago
(21%) and Bogota (20%); lower prevalence was found in
Lima (18%), Buenos Aires (17%), and Quito (14%).
Overall, metabolic syndrome was more prevalent in
women than men (22% vs 20%, respectively), with the
exception of Buenos Aires and Barquisimeto where more
men than women had metabolic syndrome. As expected,
the prevalence of metabolic syndrome increased with age.
In all cities, women showed markedly greater increase in
metabolic syndrome with increasing age than men; in the
oldest age group, female prevalence (range 25% to 49%)
was greater than male prevalence (range 13% to 38%) in
Table 1: Prevalence (%) (95% confidence interval) in the nondiabetic population* of the Metabolic Syndrome, according to NCEP ATP 
III.
Age group
25 - 34 35 - 44 45 - 54 55 - 64 Overall prevalence
Barquisimeto
Men 19.7 (13.1-26.2) 27.2 (20.7-33.7) 32.4 (25.5-39.4) 38.1 (30.7-45.5) 23.0 (19.1-27.0)
Women 11.6 (7.2-16.0) 23.9 (19.2-28.6) 37.7 (32.3-43.1) 47.8 (41.8-53.8) 22.7 (20.0-25.3)
Bogota
Men 10.7 (6.2-15.1) 18.5 (13.1-23.8) 25.9 (20.4-31.4) 30.1 (22.9-37.3) 14.7 (11.8-17.5)
Women 8.3 (4.6-11.9) 16.8 (10.8-22.7) 36.2 (30.2-42.3) 48.6 (41.8-55.5) 18.2 (15.5-20.9)
Buenos Aires
Men 11.8 (7.2-16.4) 21.8 (15.7-27.9) 26.6 (20.3-32.9) 33.0 (26.0-40.0) 17.3 (14.8-19.8)
Women 3.3 (0.8-5.9) 7.5 (3.6-11.4) 16.9 (10.4-23.5) 24.6 (17.8-31.4) 9.7 (7.1-12.3)
Lima
Men 10.0 (5.9-14.2) 15.8 (9.0-22.5) 19.8 (14.1-25.4) 25.1 (18.2-32.1) 13.2 (10.6-15.8)
Women 6.4 (3.2- 9.7) 18.7 (12.9-24.4) 34.8 (28.8-40.7) 36.8 (29.5-44.0) 17.6 (15.0-20.1)
Mexico City
Men 22.2 (15.6-28.8) 22.6 (17.7-27.6) 33.5 (28.0-39.0) 37.2 (30.6-43.7) 22.4 (18.9-25.8)
Women 16.5 (11.9-21.1) 27.4 (20.3-34.5) 35.5 (30.0-40.9) 49.3 (42.4-56.1) 22.2 (19.1-25.4)
Quito
Men 3.6 (0.7- 6.5) 6.3 (3.5- 9.1) 12.9 (8.2-17.6) 13.4 (8.6-18.2) 5.5 (3.9-7.1)
Women 7.8 (3.6-12.1) 18.0 (11.8-24.2) 35.5 (29.3-41.6) 37.4 (31.1-43.7) 16.4 (13.5-19.3)
Santiago
Men 9.9 (5.8-14.0) 17.5 (12.0-23.0) 27.0 (20.8-33.1) 31.5 (25.5-37.4) 15.3 (12.8-17.9)
Women 11.6 (7.3-15.9) 22.3 (16.0-28.6) 26.1 (20.4-31.7) 42.4 (36.4-48.5) 19.0 (16.0-22.0)
*CARMELA participants excluding participants with fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dL) and/or self-reported diabetes.Cardiovascular Diabetology 2009, 8:52 http://www.cardiab.com/content/8/1/52
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all cities except Buenos Aires (See Table 1 and Figure S1 in
additional file 1). Of components of metabolic syndrome,
the abdominal obesity was notably more prevalent in
women than men, and the difference was accentuated in
successively older age groups.
Prevalence of Specific Components of the Metabolic 
Syndrome
Table 2 reports the prevalence of each component of the
metabolic syndrome within the population of all partici-
pants with metabolic syndrome (with or without a history
of diabetes mellitus). Overall, 86% had high triglycerides,
86% had low HDL-C, and 60% were hypertensive. Across
cities, abdominal obesity was present in 81% to 93% of
women, and in 46% to 73% of men with metabolic syn-
drome.
Prevalence of the Metabolic Syndrome in Participants 
With Specific Components
Prevalence of the metabolic syndrome in subsets of the
overall population with specific components of the syn-
drome is reported in Table 3. Overall, approximately two-
thirds of men with abdominal obesity or glucose abnor-
malities, and approximately 60% to 70% of women with
high triglycerides, hypertension, or glucose abnormalities
had the full metabolic syndrome. In all cities except Mex-
ico City, the prevalence of metabolic syndrome among
participants with low HDL-C was fairly low. Prevalence of
the syndrome among women with high triglycerides was
notably higher than among men in all cities except
Barquisimeto and Buenos Aires.
Prevalence of Metabolic Syndrome Among Participants 
Without Diabetes
Table 4 reports the prevalence of the number of compo-
nents of the metabolic syndrome among CARMELA par-
ticipants without a history of diabetes mellitus. In all
cities, >60% of the participants had at least 1 component
of the metabolic syndrome. As in the overall CARMELA
population, the prevalence of metabolic syndrome in the
nondiabetic population was higher in women than men,
except in Barquisimeto and Buenos Aires.
Metabolic Syndrome and Carotid Atherosclerosis
In both men and women overall, mean CCAIMT
increased steeply with increasing numbers of metabolic
syndrome components (Table 5 and Figure S2 in addi-
tional file 1). Similarly, the prevalence of carotid plaque
also increased with increasing numbers of components
and overall, was approximately 50% more prevalent in
Table 2: Prevalence* and 95% confidence interval of specific components of the metabolic syndrome in population with metabolic 
syndrome
Abdominal obesity 
>102 cm in men or 
>88 cm in women
Triglycerides ≥ 1.70 
mmol/l 
(150 mg/dL)
HDL-C <1.03 mmol/l (40 
mg/dL) in men or <1.29 
mmol/l (50 mg/dL) in 
women
Blood pressure ≥ 
130/85 mm Hg or 
treatment
Glucose abnor-
malities†
Overall 76.3 (74.0-78.6) 85.9 (84.3-87.6) 85.6 (83.8-87.4) 60.1 (57.7-62.5) 31.2 (28.9-33.2)
Men 61.3 (57.2-65.5) 90.2 (88.2-92.1) 82.7 (80.2-85.2) 68.0 (64.7-71.3) 32.6 (29.5-35.7)
Women 88.1 (86.2-90.0) 82.6 (80.2-85.0) 87.9 (85.9-90.0) 53.8 (50.8-56.9) 30.1 (27.1-33.0)
Barquisimeto
Men 56.6 (49.1-64.1) 90.3 (85.9-94.8) 92.9 (89.6-96.2) 82.2 (76.7-87.8) 23.1 (17.4-28.8)
Women 84.0 (79.6-88.3) 78.7 (73.9-83.5) 96.4 (94.8-98.0) 63.6 (57.3-69.9) 19.4 (15.5-23.3)
Bogota
Men 45.8 (35.6-56.1) 92.1 (87.5-96.8) 92.9 (89.1-96.8) 57.6 (48.8-66.3) 40.6 (32.1-49.2)
Women 86.0 (81.5-90.5) 83.3 (78.3-88.2) 93.7 (90.2-97.2) 49.8 (42.2-57.4) 28.6 (22.2-34.9)
Buenos Aires
Men 73.1 (65.6-80.5) 77.5 (71.1-84.0) 67.7 (60.2-75.2) 93.2 (89.5-96.8) 31.8 (24.0-39.7)
Women 88.9 (82.9-94.9) 65.4 (56.7-74.0) 79.9 (72.4-87.3) 77.3 (68.3-86.4) 31.1 (21.3-40.9)
Lima
Men 55.3 (46.5-64.2) 87.3 (81.8-92.7) 93.4 (89.0-97.7) 70.5 (62.9-78.0) 30.7 (22.0-39.5)
Women 80.8 (75.2-86.3) 82.6 (76.9-88.4) 97.9 (95.8-100.0) 51.7 (44.3-59.1) 24.0 (18.6-29.3)
Mexico City
Men 72.7 (65.9-79.5) 93.0 (89.7-96.3) 78.0 (73.7-83.9) 58.3 (52.8-63.7) 30.4 (24.5-36.2)
Women 93.1 (90.6-95.5) 85.7 (80.0-91.3) 77.7 (73.2-82.1) 52.8 (47.3-58.2) 35.2 (27.9-42.6)
Quito
Men 48.8 (36.3-61.4) 97.9 (94.8-101.0) 83.9 (75.8-92.1) 62.3 (48.1-76.5) 33.4 (22.5-44.3)
Women 90.1 (85.5-94.7) 83.3 (79.0-87.7) 92.0 (88.9-95.1) 37.0 (28.7-45.2) 32.6 (26.1-39.1)
Santiago
Men 60.7 (51.9-69.5) 93.0 (89.6-96.3) 73.5 (66.4-80.7) 76.6 (69.1-84.0) 31.4 (24.9-37.9)
Women 90.6 (86.7-94.4) 82.9 (77.6-88.2) 86.6 (81.9-91.2) 57.1 (50.6-63.6) 31.1 (24.1-38.1)
*Prevalence among participants with metabolic syndrome, with or without previously diagnosed diabetes mellitus.
†Participants with fasting plasma glucose >6.11 mmol/l (110 mg/dL) or previous diagnosis of diabetes mellitus.Cardiovascular Diabetology 2009, 8:52 http://www.cardiab.com/content/8/1/52
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both men and women with metabolic syndrome than
those without. In all cities, mean CCAIMT and prevalence
of plaque were higher in participants with metabolic syn-
drome than those without.
Discussion
The CARMELA study reports overall prevalence of 21% of
metabolic syndrome by NCEP ATP III criteria in the 7
Latin American cities studied. Profiles of the metabolic
syndrome according to sex varied among cities. Among
the overall population and the nondiabetic population,
the highest prevalence of metabolic syndrome was found
in Barquisimeto and Mexico City. Women of Bogota,
Lima, Quito, and Santiago had greater prevalence of met-
abolic syndrome than their male counterparts, while the
opposite was true in Buenos Aires. Not surprisingly, prev-
alence of metabolic syndrome increased with age, strik-
ingly so in women. Participants with metabolic syndrome
had higher mean CCAIMT and prevalence of carotid
plaque than those without the syndrome.
The prevalence of metabolic syndrome found in CAR-
MELA approximates prevalence estimates (23% to 27%)
in the United States [6,13]. Direct comparison with other
Latin America studies using NCEP ATP III criteria show
CARMELA prevalence to be consistent with prevalence in
Mexico [17,18]. Also by NCEP ATP III criteria, 31% of a
population of Zulia State, Venezuela [19], and 12% and
26% of men and women of Lima [18], respectively, were
found to have metabolic syndrome. CARMELA reports
lower prevalence in Barquisimeto than elsewhere in Ven-
ezuela, and prevalence that is less disparate between the
sexes of Lima; however, CARMELA targeted a much
broader population base than in the aforementioned
study in Lima. In the Estudio Peruano de Prevalencia de
Enfermedades Cardiovasculares, or Peruvian Study of the
Prevalence of Cardiovascular Risk Factors (PREVEN-
CION) study in another urban region of Peru, 14% and
23% of men and women, respectively, were found to have
the syndrome [20].
Whereas it has been suggested that the burden of meta-
bolic syndrome is growing in younger populations, espe-
cially in developing regions [21], metabolic syndrome
increases with age as CARMELA results confirm. Elevated
body weight, waist circumference, and low HDL-C levels
Table 3: Prevalence (%)(95% confidence interval) of the metabolic syndrome among subsets of participants* with each of the 5 NCEP 
ATP III risk factor components of the syndrome
Abdominal obesity 
>102 cm in men or 
>88 cm in women
Triglycerides ≥ 1.70 
mmol/l 
(150 mg/dL)
HDL-C <1.03 mmol/l (40 
mg/dL) in men or <1.29 
mmol/l (50 mg/dL) in 
women
Blood pressure ≥ 
130/85 mm Hg or 
treatment
Glucose 
abnormalities†
Overall 53.3 (51.0-55.5) 45.7 (43.9-47.5) 34.6 (33.0-36.2) 52.5 (50.3-54.7) 71.6 (68.3-74.8)
Men 64.0 (60.3-67.7) 36.2 (34.0-38.4) 35.5 (33.0-38.0) 47.5 (44.7-50.2) 70.5 (66.4-74.7)
Women 48.7 (45.9-51.6) 59.0 (56.2-61.9) 34.0 (32.0-36.0) 58.7 (55.6-61.8) 72.5 (67.7-77.2)
Barquisimeto
Men 75.7 (66.9-84.5) 50.3 (44.5-56.1) 34.5 (29.1-39.9) 60.2 (53.7-66.7) 82.1 (72.9-91.2)
Women 61.1 (55.9-66.3) 66.9 (62.6-71.2) 32.4 (28.5-36.3) 59.8 (54.1-65.5) 70.3 (59.4-81.2)
Bogota
Men 77.1 (68.5-85.7) 32.1 (27.7-36.5) 29.4 (25.2-33.7) 53.1 (45.9-60.2) 71.1 (60.3-81.9)
Women 55.0 (49.0-60.9) 55.0 (48.4-61.6) 28.5 (25.2-31.9) 64.8 (56.2-73.4) 61.6 (50.1-73.1)
Buenos Aires
Men 56.6 (50.3-62.8) 57.2 (49.9-64.5) 50.1 (43.3-57.0) 38.4 (34.2-42.5) 70.8 (60.1-81.6)
Women 36.0 (29.7-42.2) 62.3 (53.1-71.4) 31.7 (25.1-38.3) 31.7 (25.1-38.4) 68.6 (55.3-81.9)
Lima
Men 73.7 (65.0-82.4) 35.1 (29.4-40.7) 22.9 (18.9-26.8) 46.4 (39.1-53.6) 74.5 (63.2-85.8)
Women 50.9 (44.3-57.5) 61.5 (55.2-67.8) 24.3 (21.1-27.5) 64.1 (56.7-71.5) 76.6 (65.7-87.4)
Mexico City
Men 59.6 (52.4-66.8) 38.3 (33.6-43.0) 58.8 (51.7-65.9) 61.8 (55.2-68.5) 71.1 (64.7-77.4)
Women 46.7 (40.2-53.2) 59.3 (53.5-65.1) 53.0 (47.1-58.9) 67.7 (60.3-75.1) 79.5 (71.6-87.5)
Quito
Men 66.2 (52.3-80.1) 14.5 (11.1-17.9) 22.6 (16.9-28.2) 34.1 (25.7-42.5) 44.5 (31.8-57.2)
Women 46.2 (40.9-51.5) 51.3 (42.9-59.7) 38.6 (32.8-44.4) 62.2 (53.7-70.7) 71.9 (62.1-81.7)
Santiago
Men 61.1 (52.6-69.7) 36.4 (31.5-41.3) 44.8 (38.4-51.1) 39.5 (34.1-44.8) 68.1 (58.8-77.3)
Women 47.8 (42.6-52.9) 61.9 (56.1-67.8) 43.3 (37.8-48.9) 57.6 (51.7-63.5) 74.9 (65.4-84.5)
*All participants, with or without diabetes mellitus, were grouped by presence of specific components, and prevalence of metabolic syndrome 
within each group is reported here.
†All participants with fasting plasma glucose >6.11 mmol/l (110 mg/dL) or previous diagnosis of diabetes mellitus.Cardiovascular Diabetology 2009, 8:52 http://www.cardiab.com/content/8/1/52
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have been found to be more common contributors to
metabolic syndrome in women, while blood pressure and
apolipoprotein B have been found to be more common
contributors in men [22]. Obesity in women is increasing
faster than in men [23] and the metabolic syndrome
increases in a parallel manner. In many women, meno-
pause is accompanied by the emergence of features of the
metabolic syndrome and increased cardiovascular risk,
whether as a direct result of ovarian failure or indirectly
related to central adipose redistribution [23,24]. With this
constellation of factors, it has even been suggested that the
metabolic syndrome should be defined by different crite-
ria in men and women [22]. CARMELA results illustrate
the amplified increase in metabolic syndrome in women
as opposed to men as women reach menopausal age. A
study of post-menopausal Ecuadorian women [25]
revealed an overall prevalence of metabolic syndrome of
42%, similar to that found in CARMELA, with prevalence
of hypertension, abdominal obesity, and low HDL-C sim-
ilar to that in women in the older 2 CARMELA age groups.
In a broader study of postmenopausal Latin American
women, rates of metabolic syndrome in women of Bue-
Table 4: Prevalence (%) (95% confidence interval) in the nondiabetic population* of 1 to 5 of the NCEP ATP III risk factor components 
of the metabolic syndrome and diagnosis of metabolic syndrome
Number of Components
0123 4 5
Overall 23.4 (22.3-24.5) 32.8 (31.7-34.0) 26.5 (25.4-27.6) 13.0 (12.2-13.8) 4.0 (3.6-4.4) 0.3 (0.2-0.4)
Men 24.6 (23.1-26.2) 30.8 (29.1-32.4) 28.5 (26.9-30.0) 12.2 (11.1-13.4) 3.6 (3.0-4.1) 0.3 (0.1-0.5)
Women 22.3 (20.8-23.8) 34.7 (33.0-36.3) 24.8 (23.3-26.2) 13.7 (12.5-14.8) 4.3 (3.8-4.9) 0.3 (0.1-0.4)
Barquisimeto
Men 14.1 (11.2-16.7) 32.6 (28.3-37.0) 30.3 (26.5-34.1) 15.8 (12.8-18.8) 6.7 (4.7-8.8) 0.5 (0.0-1.0)
Women 13.4 (10.9-16.0) 37.5 (33.8-41.2) 26.4 (23.4-29.5) 16.3 (14.0-18.5) 6.2 (4.7-7.8) 0.2 (0.0-0.3)
Bogota
Men 21.6 (18.1-25.0) 30.7 (26.6-34.9) 33.0 (29.4-36.6) 11.4 (8.6-14.2) 3.0 (1.8-4.1) 0.3 (0.0-0.7)
Women 17.6 (14.3-20.9) 35.4 (31.9-38.9) 28.8 (25.5-32.1) 14.0 (11.2-16.8) 4.0 (2.9-5.2) 0.2 (0.0-0.4)
Buenos Aires
Men 28.5 (25.1-31.9) 30.2 (27.3-33.1) 24.0 (20.4-27.5) 12.7 (10.5-15.0) 4.4 (2.9-5.9) 0.2 (0.0-0.5)
Women 37.7 (33.8-41.5) 36.7 (32.8-40.6) 15.9 (13.0-18.8) 7.5 (5.4-9.6) 2.1 (0.8-3.3) 0.1 (0.0-0.4)
Lima
Men 21.5 (18.0-25.0) 35.8 (32.0-39.7) 29.5 (26.0-33.0) 9.7 (7.5-11.8) 3.2 (1.9-4.5) 0.3 (0.0-0.6)
Women 12.1 (9.5-14.7) 44.2 (40.4-48.1) 26.1 (22.7-29.5) 13.2 (10.9-15.3) 4.2 (3.0-5.5) 0.2 (0.0-0.5)
Mexico City
Men 23.7 (20.5-27.0) 26.0 (23.4-28.5) 27.9 (24.7-31.1) 17.3 (14.1-20.5) 4.6 (3.2-6.0) 0.5 (0.0-1.0)
Women 24.3 (20.7-27.8) 27.5 (24.1-31.0) 26.0 (22.9-29.0) 16.7 (14.0-19.4) 5.0 (3.7-6.3) 0.5 (0.0-1.0)
Quito
Men 39.2 (34.8-43.5) 32.5 (28.9-36.0) 22.8 (19.8-25.9) 4.3 (2.9-5.8) 1.1 (0.4-1.8) 0.1 (0.0-0.2)
Women 30.5 (26.9-34.1) 30.9 (27.2-34.5) 22.2 (18.8-25.7) 13.4 (10.8-16.1) 2.7 (1.7-3.6) 0.3 (0.0-0.6)
Santiago
Men 28.6 (24.5-32.6) 29.8 (25.6-33.9) 26.3 (22.7-29.9) 11.7 (9.5-14.1) 3.3 (2.0-4.5) 0.3 (0.0-0.7)
Women 28.6 (24.8-32.3) 30.5 (26.9-34.2) 21.9 (19.1-24.8) 13.3 (10.8-15.8) 5.5 (3.8-7.1) 0.2 (0.0-0.5)
*CARMELA participants excluding participants with fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dL) and/or self-reported diabetes.
Table 5: Mean CCAIMT (mm), prevalence (%) and 95% confidence intervals, of carotid plaque according to the number of components 
of the metabolic syndrome by NCEP ATP III criteria in the CARMELA participants*
Number of 
components
012 3 4 5N o  
metabolic 
syndrome
Metabolic 
syndrome
Mean CCAIMT
Men 0.623
(0.616-0.629)
0.644
(0.637-0.650)
0.665
(0.658-0.672)
0.688
(0.679-0.697)
0.707
(0.694-0.720)
0.731
(0.701-0.761)
0.645
(0.640-0.650)
0.695
(0.687-0.702)
Women 0.624
(0.617-0.632)
0.624
(0.618-0.631)
0.645
(0.639-0.652)
0.668
(0.662-0.675)
0.709
(0.696-0.721)
0.704
(0.685-0.723)
0.631
(0.626-0.636)
0.682
(0.676-0.688)
Prevalence of carotid plaque
Men 4.0 (2.7-5.2) 7.2 (5.7-8.6) 7.8 (6.2-9.4) 9.3 (6.9-11.7) 9.7 (5.9-13.4) 11.4 (3.4-19.4) 6.4 (5.5-7.4) 9.5 (7.4-11.6)
Women 4.9 (3.5-6.2) 7.4 (5.9-8.8) 7.8 (6.3-9.4) 10.9 (8.5-13.3) 11.7 (8.1-15.4) 12.5 (6.2-18.8) 6.8 (5.9-7.7) 11.2 (9.3-13.2)
*CARMELA survey participants, including those with previous history of diabetes mellitus.
CCAIMT = carotid artery intima-media thicknessCardiovascular Diabetology 2009, 8:52 http://www.cardiab.com/content/8/1/52
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nos Aires were higher and those of Bogota, Lima, and San-
tiago, similar to those of women in the oldest 2 CARMELA
age groups [26]. Although in all CARMELA cities, older
women showed strikingly higher abdominal obesity rates
than men, high rates of abdominal obesity were found in
women of all age groups.
In designing targeted programs for detection and treat-
ment of metabolic syndrome, CARMELA provides crucial
data on the sensitivity and predictive value of each com-
ponent. On the one hand, of the general population of
men in CARMELA cities (except for Quito where lower
prevalence of metabolic syndrome in men is noted),
approximately 70% of those with glucose abnormalities,
approximately two-thirds of those with abdominal obes-
ity, and half with hypertension, will have the full syn-
drome. Of the general population of women in CARMELA
cities, nearly three-quarters of those with glucose abnor-
malities, and approximately 50% to 60% with abdominal
obesity, high triglycerides, or hypertension, will have the
full metabolic syndrome (Table 2). On the other hand,
once metabolic syndrome is diagnosed, the shape of the
syndrome is characterized by predominance of hyperten-
sion, low HDL-C and high triglycerides in men, and pre-
dominance of abdominal obesity, high triglycerides, and
a remarkable predominance of low HDL-C in women
(Table 3). Thus, hypertension, low HDL-C, and high trig-
lycerides in men and low HDL-C in particular, along with
high triglycerides and abdominal obesity in women, are
highly specific indicators of the syndrome. CARMELA pro-
vides data which confirms the likelihood of finding other
specific components, once metabolic syndrome is diag-
nosed. Although the metabolic syndrome predicts diabe-
tes along with cardiovascular risk, glucose abnormalities
in and of themselves are not particularly specific to the full
syndrome. This notion is confirmed by the similar preva-
lence of metabolic syndrome in CARMELA populations
that both include and exclude diabetes. Since the meta-
bolic syndrome is epitomized by the development of dia-
betes, its presence in the nondiabetic population is of
particular importance.
To our knowledge, this is the first study that provides evi-
dence of a relationship between the occurrence of the met-
abolic syndrome and the presence of carotid
atherosclerosis in the Latin American population. A large
study in Italy reported increased incidence of carotid
plaques and stenosis over 5 years of follow-up in partici-
pants with metabolic syndrome [9]. Metabolic syndrome
has also been associated with incident stroke in both
black and white populations in the United States [6] and
with higher carotid intima-media thickness and preva-
lence of plaques in elderly French individuals [27]. Meta-
bolic syndrome has also been associated with tissue
characteristics of the intima-media complex in the carotid
artery [28], and the increasing number of components of
the metabolic syndrome have also been related to higher
carotid artery stiffness [29]. In other studies, the associa-
tion between metabolic syndrome and carotid atheroscle-
rosis has been reported to be stronger in women than men
[30], however, in the CARMELA study it seems to be quite
similar for men and women. Carotid intima-media thick-
ening as an indicator of atherosclerosis in other vascular
beds [31] is a strong predictor of future cardiovascular
events [32]. The relationship between metabolic syn-
drome and carotid atherosclerosis noted in CARMELA
enhances previous findings of metabolic syndrome as a
cardiovascular disease predictor [3,7,9].
The value of CARMELA lies in its carefully constructed
sampling of populations by age and sex to elucidate prev-
alence of metabolic syndrome components. Urban vs
rural and ethnic differences in prevalence of metabolic
syndrome have been reported in a variety of Latin Ameri-
can settings [33] and should be investigated further.
Genetic predispositions to the metabolic syndrome [34],
along with cultural and nutritional variations, also need
investigation given Latin America's unique conglomera-
tion of indigenous and immigrant populations. The obes-
ity epidemic clearly affects the prevalence of metabolic
syndrome among women but also extends to the young;
CARMELA's lowest age range (25 to 34 years) may not
have fully encompassed populations at risk, nor did CAR-
MELA include increasingly older populations, which until
now have borne the brunt of chronic disease. Rigorous
studies like CARMELA should aid in designing targeted
solutions to increasing rates of metabolic syndrome and
its consequences.
In the Shape of the Nations Survey, 39% of participants
worldwide who visited primary care physicians were over-
weight or obese, but only 58% of primary care physicians
recognized that abdominal obesity was a significant risk
factor for cardiovascular disease, and 45% reported that
they never measured waist circumference [35]. As alarm-
ing as these statistics are, CARMELA findings reinforce the
notion that metabolic syndrome is prevalent in urban
Latin America and should be sought in the presence of
even 1 component of the syndrome. Likewise, carotid
atherosclerosis in Latin American individuals should spur
healthcare providers to seek evidence of metabolic syn-
drome components and effect appropriate interventions.
Guidelines for treatment of specific components in the
context of the full metabolic syndrome are being devel-
oped [2] and should be promoted by healthcare educators
and providers. The chronic disease burden consequent to
metabolic syndrome will be extensive and expensive in
Latin America if studies like CARMELA are ignored.Cardiovascular Diabetology 2009, 8:52 http://www.cardiab.com/content/8/1/52
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Conclusion
CARMELA reports high prevalence of metabolic syn-
drome in 7 Latin American cities. Although rates varied
between cities, there was a striking increase in the preva-
lence of metabolic syndrome with age, especially in
women. CARMELA provides evidence for the association
of metabolic syndrome with evidence of carotid athero-
sclerosis--namely increasing mean CCAIMT and plaque
with increasing numbers of components of the syndrome,
and overall higher mean CCAIMT and plaque in partici-
pants with the syndrome compared with those without. It
is incumbent on government agencies and the medical
community to address current prevalence of metabolic
syndrome in order to prevent the dire consequences of
increased burden of disease.
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